News

This week's edition features stories in consumer media involving sunscreen terms, facial erythema, inner thigh chafing, pityrosporum folliculitis, how to treat "maskne," plus more.

ICYMI, some of the stories featured this week include a look at the impact of apremilast treatment for psoriasis on a patient who also tested positive for COVID-19, exploring IL-17 inhibition for rosacea, FDA approvals for a cellulite injectable and atopic dermatitis treatment, plus more.

The U.S. Food and Drug administration has accepted the Biologics License Application for tralokinumab (LEO Pharma) for moderate-to-severe atopic dermatitis and is expected to make a decision in the second quarter of 2021.

With summer in full swing, this episode takes a look at how social media can influence sun protection use in teens and young adults, and why certain ingredients in sunscreens are considered controversial.

The U.S. FDA has approved collagenase clostridium histolyticum-aaes (Qwo, Endo International), making it the first FDA-approved injectable treatment for moderate-to-severe cellulite in the buttocks in adult women.

This week we feature articles about the rise in plastic surgery procedures and 'tweakments' during the COVID-19 pandemic, uses for aloe vera in skincare, retinol use for acne, plus more.

ICYMI, this week’s edition features a warning from the FDA about potentially toxic hand sanitizers, the latest data from the phase 3 bimekizumab trial for psoriasis, gene expression profiling for skin cancer, PRP for periorbital rejuvenation, plus more.

The U.S. Food and Drug Administration (FDA) has issued a warning about potentially toxic hand sanitizers.

SanovaWorks announces they are moving their annual Skin of Color Update 2020 to a virtual setting amid various other live event cancellations due to the COVID-19 pandemic.

In this week's edition, we feature articles about expired sunscreen, uses for cortisone cream, Johnson & Johnson deciding to stop selling skin lightening products overseas, a warning from the FDA about possible toxic hand sanitizers, plus more.

The U.S. Food and Drug Administration has approved a single-dose 300 mg pre-filled pen version of dupilumab (Dupixent, Sanofi and Regeneron) for the treatment of atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP) in U.S. patients 12 years and older.

Almirall announces the U.S. Food and Drug Administration has approved the updated label for their oral antibiotic sarecycline (Seysara) for treatment of acne vulgaris to help promote the appropriate use of the drug to aid in preventing antimicrobial resistance commonly warned when using antibiotics

ICYMI, this week’s edition features a video series on social media use in dermatology, the launch of our new podcast, as well as articles about FDA approvals for acne and cSCC, progress in epidermolysis bullosa, new rosacea management treatment, plus more.

The U.S. Food and Drug Administration has approved the Abbreviated New Drug Application for topical retinoid adapalene gel USP, 0.3% from Alembic Pharmaceuticals and its joint venture Aleor Dermaceuticals for treatment of acne vulgaris.

In the final installment of our conversation with Adam Friedman, M.D., FAAD, he details what dermatologists should keep in mind when posting to social media.

Tazarotene lotion 0.045% (Arazlo, Ortho Dermatologics) is officially launched in the U.S. following approval by the U.S. Food and Drug Administration in late 2019 for the treatment of acne vulgaris in patients 9 years and older.

In part three of our video interview with Adam Friedman, M.D., FAAD, he discusses some of the benefits and pitfalls of colleague-to-colleague engagement on social media.

The U.S. Food and Drug Administration has approved pembrolizumab for cutaneous squamous cell carcinoma whose disease has shown to not be curable by radiation or surgery.

In our first episode of The Cutaneous Connection, Adam Friedman, M.D., FAAD, discusses his recent presentation at the first virtual American Academy of Dermatology meeting about cannabinoids use in dermatology.

In part two of our conversation with Adam Friedman, M.D., FAAD, he offers insight on which patients look for a dermatologist on social media and what types of content produce the most engagement online.

Gusacitinib, an investigational oral Janus kinase/spleen tyrosine kinase inhibitor, demonstrated statistical superiority compared with placebo for improving chronic hand eczema in a phase 2b study.

In this week's edition, we feature stories about dry brushing, the difference between psoriasis and eczema, comedone extractors, at-home microneedling, plus more.

ICYMI, this week’s edition features articles about laser therapy for BCC, the growing interest in JAK-STAT inhibition, tips on how to sell your practice, apremilast for scalp pruritus, plus more.

Evidence Skincare is now offering consumers a complementary skin survey to help identify consumers' problem areas, recommend skincare regimens and provide suggestions on what products might work best for them.

The Inaugural Pediatric Dermatology 2020: Best Practices and Innovations Conference is now open for registration and scheduled to take place June 27th, offering seven free CME credits.

A startup from Purdue University seeks to make handwashing easier and more accessible during COVID-19 through its new portable bedside sink technology developed by Project Process.

In this week’s edition, we feature stories about black-owned skincare lines, polyglutamic acid, hair antioxidants, a skincare company making affordable custom topical prescriptions, plus many more.

ICYMI, we've curated a list of all the stories we've published throughout the past week. Check out this article for more Dermatology Times content.

LEO Pharma will soon begin marketing its monoclonal antibody tralokinumab for atopic dermatitis with the announcement that the EMA has accepted the marketing authorization application for the drug.

Dermavant announces the enrollment completion for their long-term safety study investigating tapinarof in adults with plaque psoriasis as a part of the PSOARING 1 and PSOARING 2 phase 3 program.